BioStock: Chordate Medical's CEO comments on recent successes and future plans
Over the past month, many pieces of the puzzle have fallen into place for Chordate Medical. The key piece was the CE marking in migraines that led to an initial order for the migraine treatment system from Vedise Hospital in Italy. The company's migraine study has been restarted in Germany, and now the plan is to treat the last patient in the study during Q3 2021. BioStock contacted the company's CEO Anders Weilandt to hear his thoughts on recent events, but also to find out what lies ahead.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se